MINERALYS THERAPEUTICS, INC. Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current
MINERALYS THERAPEUTICS, INC. (MLYS) had Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current of $166.33 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Debt Securities, Current
us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossCurrent · last filed 2025-02-12
- 2024-09-30: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current $166.33M.
- 2024-06-30: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current $243.26M.
- 2024-03-31: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current $248.15M.
- 2023-12-31: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current $187.26M.
| Period end | Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Current |
|---|---|
| 2024-09-30 | $166.33M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $243.26M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $248.15M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $187.26M 10-K · filed 2025-02-12 |
| 2023-09-30 | $167.46M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $159.96M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $132.39M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $22.41M 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |